Posted inWire
EyePoint Pharmaceuticals announces $150 million public offering to fund retinal drug development
WATERTOWN: EyePoint Pharmaceuticals, Inc. announced Monday it has commenced an underwritten public offering of $150 million of its common stock. The biopharmaceutical company, which focuses on treatments for serious retinal…